A Phase 3 Randomized Double-Blind Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn s Disease

Brief description of study

This trial is testing an experimental drug tulisokibart (MK-7240) in people with moderately to severely active Crohn’s disease (CD). This trial will compare tulisokibart to placebo. A placebo looks like a trial drug, but it has no active ingredients.

The purpose of this trial is to test the safety of the trial drug, tulisokibart, and see how well tulisokibart works, compared to placebo,

The trial drug you get will depend on which group you are placed in. Study 1 has 4 groups:

Groups 1, 2, and 3 will get different doses of tulisokibart.
Group 4 will get placebo only.

Clinical Study Identifier: s24-00474

ClinicalTrials.gov Identifier: NCT06430801

Principal Investigator: David P Hudesman.

Other Investigators: Adam Faye, Ariela Holmer, Simon J Hong, Jordan E Axelrad, Shannon Chang.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies